Role of human immunodeficiency virus type 1 group O in the AIDS pandemic

AIDS Reviews

Volumn 2, Issue 3, 2000, Pages 190-202

  Quinones Mateu M E ^a   Ball, S C ^a   Arts, E J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diversity; Evolution; Group O; HIV; Subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VACCINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CAMEROON; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE TRANSMISSION; DRUG DESIGN; DRUG EFFICACY; EPIDEMIC; GENE CLUSTER; GENE ISOLATION; GENE MAPPING; GENE SEQUENCE; GENE STRUCTURE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MOLECULAR EVOLUTION; MOLECULAR GENETICS; NONHUMAN; PHENOTYPE; PHYLOGENY; POPULATION RESEARCH; REVIEW; SAMPLE; VIRAL GENETICS; VIRUS CLASSIFICATION; VIRUS LOAD; VIRUS STRAIN;

EID: 0034544542     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. A reference guide to HIV-1 classification
2. HIV-1 nomenclature proposal
3. AIDS as a zoonosis: Scientific and public health implications
4. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes
5. Env sequences of simian immunodeficiency viruses from chimpanzees in Cameron are strongly related to those of human immunodeficiency virus group N from the same geographic area
6. Timing the ancestor of the HIV-1 pandemic
7. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central african origin
8. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate
9. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon
10. Isolation and envelope sequence of a highly divergent HIV-1 isolate: Definition of a new HIV-1 group
11. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France
12. Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon
13. Sequence of gp41env immunodominant region of HIV type 1 group O from West Central Africa
14. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from Equatorial Guinea
15. Seroprevalence of HIV-1, HIV-2, and HIV-1 group O in Nigeria: Evidence for a growing increase of HIV infection
16. Geographical distribution of HIV-1 group O viruses in Africa
17. HIV-1 group O and group M dual infection in Benin
18. HIV-1 group O virus infection in Abidjan, Cote d'Ivoire
19. Presence of HIV-1 group O infection in West Africa
20. Surveillance for HIV-1 subtypes O and M in Kenya
21. Antigenic evidence of the presence of the aberrant HIV-1ant70 virus in Cameroon and Gabon
22. Serological and virological characterization of HIV-1 group O infection in Cameroon
23. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients
24. The Cote d'Ivoire national HIV counseling and testing program for tuberculosis patients: Implementation and analysis of epidemiologic data
25. First case of HIV subtype O infection in Germany
26. First case of HIV-1 group O infection in Spain
27. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1
28. Sequence analysis of HIV-1 group O from norwegian patients infected in the 1960s
29. Identification of HIV-1 group O infection - Los Angeles County, California
30. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States
31. Env gene characterization of the first HIV type 1 group O Spanish isolate
32. Tropism, coreceptor use, and phylogenetic analysis of both the V3 loop and the protease gene of three novel HIV-1 group O isolates
33. Antiretroviral therapy selects for drug resistance and drives independent evolution in protease, RT, and env of HIV-1 group O isolates
34. Genetic analysis of HIV type 1 group O p24gag sequences from Cameroon and Equatorial Guinea
35. Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O
36. Genetic characterization of accessory genes from human immunodeficiency virus type 1 group O strains
37. Phylogeny of HIV type 1 group O isolates based on env gene sequences
38. Interpatient genetic variability of HIV-1 group O
39. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections
40. Reactivity of a new HIV-1 group O third generation A-HIV-1/-2 assay with an unusual HIV-1 seroconversion panel and HIV-1 group O/group M sub-typed samples
41. Diagnosis of HIV-1 group O infection by polymerase chain reaction
42. Differential diagnosis of HIV type 1 group O and M infection by polymerase chain reaction and Pstl restriction analysis of the pol gene fragment
43. Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group O
44. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
45. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma
46. Subtype-specific problems with quantification of plasma HIV-1 RNA
47. HIV-1 subtypes and plasma RNA quantification
48. Detection of genetically diverse human immunodeficiency virus type 1 group M and O isolated by PCR
49. Clinical evaluation of an LTR based HIV-1 RNA load NASBA for detection of HIV-1 M and O-group viruses
50. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1
51. Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity
52. Concerted action HIV variability. The history of HIV-1 biological phenotypes. Past, present and future
53. HIV-1 subtype and second-receptor use
54. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1
55. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
56. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1
57. Coreceptor requirements of primary HIV type 1 group O isolates from Cameroon
58. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
59. V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells
60. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
61. Cyclophillin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIVcpzGAB but not group O HIV-1 or other primate immunodeficiency viruses
62. Phosphorylation of Vif and its role in HIV-1 replication
63. Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1
64. Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains
65. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus
66. Diversity of the immunodominant epitope of gp41 of HIV-1 subtype O and its validity for antibody detection
67. HIV-1 Langerhan's cell tropism associated with heterosexual transmission of HIV
68. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups
69. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism
70. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D
71. Human immunodeficiency virus type 1 subtypes differ in disease progression
72. First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child
73. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants
74. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate
75. Interactions between HIV and the host immune system in the pathogenesis of AIDS
76. Adaptative evolution of human immunodeficiency virus-type 1 during the natural course of infection
77. HIV-1 group O sensitivity to antiretroviral drugs
78. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses
79. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility
80. Mutations in retroviral genes associated with drug resistance
81. Genotypic subtypes in HIV-1 in Cameroon
82. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses
83. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic
84. Triple HIV-1 infection with group O and Group M of different clades in a single Cameroonian AIDS patient
85. Epidemiological and molecular characteristics of HIV infection in Gabon 1986